Anzeige
Mehr »
Mittwoch, 29.04.2026 - Börsentäglich über 12.000 News
250 Tage bis zum Pentagon-Magnetverbot: Wie ein 46-Mio.-CAD-Small-Cap profitieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ECGB | ISIN: US34965K1079 | Ticker-Symbol: K67
Tradegate
24.04.26 | 15:45
8,000 Euro
-13,04 % -1,200
1-Jahres-Chart
FORTREA HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
FORTREA HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,1009,30014:19
9,1009,30014:19
GlobeNewswire (Europe)
309 Leser
Artikel bewerten:
(2)

Fortrea Holdings Inc: Fortrea Unveils Fortrea Intelligent Technology to Help Sponsors and Sites Run Smarter, More Integrated Trials

AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality

Highlights:

  • Designed to transform clinical trial operations for sponsors, sites and study teams
  • Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality
  • Builds on Fortrea's flagship platform Xcellerate to deliver near-real-time, role-based insights

DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology(FIT), a suite of innovative technology solutions designed to transform clinical trial operations.

By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality.

An Innovative, Intelligent Suite of Clinical Solutions
FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem.

The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS).

FIT solutions are arranged into three pillars:

  • Lifecycle: Deliver Trials Faster with Confidence
    Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF.

  • Foresight: Turn Data into Actionable Insights
    Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight.

  • Companion: Empowering Study Teams to Work Smarter
    Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration.

"We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus," said Chief Information Officer Alejandro Martinez Galindo. "Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk."

Xcellerate Anchors the Intelligent Suite
Xcellerate, Fortrea's platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering.

Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research.

"We expect these Xcellerate enhancements and the broader FIT platform will be game changers for our study teams and our clients," said Chief Operating Officer and President, Clinical Development Mark Morais. "Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us-all of which can make the difference in getting life-changing treatments to patients faster and more efficiently."

Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts:
Jennifer Minx (Media) - 919-410-4195, media@fortrea.com
Kate Dillon (Media) - 646-818-9115, kdillon@prosek.com
Tracy Krumme (Investors) - 984-385-6707, Tracy.Krumme@fortrea.com


© 2026 GlobeNewswire (Europe)
Vergessen Sie Gold, Silber und Öl: Nächste Megarallye startet!
Die Märkte feiern neue Rekorde – doch im Hintergrund braut sich eine Entwicklung zusammen, die alles verändern könnte. Die anhaltende Sperrung der Straße von Hormus sorgt laut IEA für eine der größten Energiekrisen aller Zeiten. Gleichzeitig schießen die Preise für Düngemittel und Agrarrohstoffe bereits nach oben.

Damit droht ein perfekter Sturm: steigende Energiepreise, explodierende Produktionskosten und ein möglicher Super-El-Nino, der weltweit Ernten gefährdet. Erste Auswirkungen sind längst sichtbar – Weizen, Soja und Kakao verteuern sich deutlich, während Lebensmittelpreise vor dem nächsten Sprung stehen könnten.

Für Anleger bedeutet das nicht nur Risiken, sondern enorme Chancen. Denn während klassische Märkte unter Druck geraten könnten, entsteht auf den Feldern und Plantagen der nächste große Rohstoffzyklus. Wer sich jetzt richtig positioniert, kann von einer Entwicklung profitieren, die weit über Öl und Metalle hinausgeht.

In unserem aktuellen Spezialreport stellen wir drei Aktien vor, die besonders aussichtsreich sind, um von diesem Trend zu profitieren – solide positioniert, strategisch relevant und mit erheblichem Aufwärtspotenzial.



Jetzt den kostenlosen Report sichern – bevor der Agrar-Boom voll durchschlägt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.